MX363240B - Composiciones que inhiben la influenza y métodos. - Google Patents

Composiciones que inhiben la influenza y métodos.

Info

Publication number
MX363240B
MX363240B MX2014004158A MX2014004158A MX363240B MX 363240 B MX363240 B MX 363240B MX 2014004158 A MX2014004158 A MX 2014004158A MX 2014004158 A MX2014004158 A MX 2014004158A MX 363240 B MX363240 B MX 363240B
Authority
MX
Mexico
Prior art keywords
protein
peptide
influenza
fir
wild
Prior art date
Application number
MX2014004158A
Other languages
English (en)
Inventor
F Garry Robert
B Wilson Russell
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of MX363240B publication Critical patent/MX363240B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

La presente invención proporciona péptidos, análogos de péptido, derivados de péptido y composiciones farmacéuticas útiles para tratar o prevenir infecciones de influenza o prevenir la transmisión de persona a persona de una infección de influenza. Un péptido de la invención que comprende una porción que inhibe la fusión del virus de influenza-célula de la región de iniciación de fusión (FIR) de una proteína de hemaglutinina 2 de influenza de tipo silvestre o una variante de la misma. En una modalidad preferida, un péptido de la invención consiste de 8 a 40 residuos de aminoácidos consecutivos de una porción de una proteína de hemaglutinina 2 de influenza de tipo silvestre o una variante de la misma, la porción de la proteína que comprende la FIR de la proteína y hasta cinco residuos de aminoácidos sobre los lados amino terminal y carboxi terminal de la FIR.
MX2014004158A 2007-06-25 2008-06-25 Composiciones que inhiben la influenza y métodos. MX363240B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93712007P 2007-06-25 2007-06-25
PCT/US2008/007918 WO2009002516A1 (en) 2007-06-25 2008-06-25 Influenza inhibiting compositions and methods

Publications (1)

Publication Number Publication Date
MX363240B true MX363240B (es) 2019-03-15

Family

ID=40185954

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009013635A MX2009013635A (es) 2007-06-25 2008-06-25 Composiciones que inhiben la influenza y metodos.
MX2014004158A MX363240B (es) 2007-06-25 2008-06-25 Composiciones que inhiben la influenza y métodos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009013635A MX2009013635A (es) 2007-06-25 2008-06-25 Composiciones que inhiben la influenza y metodos.

Country Status (18)

Country Link
US (2) US8604165B2 (es)
EP (1) EP2170365B1 (es)
JP (2) JP5450402B2 (es)
KR (4) KR101660363B1 (es)
CN (2) CN105237629B (es)
BR (1) BRPI0813922A2 (es)
CA (1) CA2691358C (es)
DK (1) DK2170365T3 (es)
EA (1) EA017957B1 (es)
ES (1) ES2581381T3 (es)
HK (2) HK1142804A1 (es)
HU (1) HUE029921T2 (es)
IL (2) IL202450A (es)
MX (2) MX2009013635A (es)
PL (1) PL2170365T3 (es)
PT (1) PT2170365T (es)
WO (1) WO2009002516A1 (es)
ZA (1) ZA200909130B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110126501A1 (en) 2009-10-16 2011-06-02 Woongjin Coway Co., Ltd. Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter
KR101153630B1 (ko) * 2009-10-16 2012-06-18 웅진코웨이주식회사 타닌산을 포함하는 인플루엔자 바이러스 감염의 예방용 조성물, 상기 조성물을 포함하는 기상필터 및 상기 필터를 포함하는 공기청정기
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
US20180128545A1 (en) * 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
WO2018102753A1 (en) * 2016-12-02 2018-06-07 Emory University Peptides and uses for managing viral infections
WO2021226533A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
CN113801206A (zh) * 2020-06-15 2021-12-17 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
WO2021253172A1 (zh) * 2020-06-15 2021-12-23 上海市公共卫生临床中心 利用受体识别域诱导抗新冠病毒中和抗体的方法
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1711888A (en) 1987-04-24 1988-12-02 Biogen, Inc. Immunotherapeutic methods and compositions
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
US5567805A (en) * 1990-03-09 1996-10-22 Administrators Of The Tulane Educational Fund The cellular receptor for the CS3 peptide of human immunodeficiency virus
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6310180B1 (en) * 1993-06-21 2001-10-30 Vanderbilt University Method for synthesis of proteins
US6037348A (en) * 1996-02-09 2000-03-14 Eli Lilly And Company Inhibition of viral replication
CA2271249C (en) * 1996-11-14 2010-07-20 Biota Scientific Management Pty. Ltd. Macromolecular neuraminidase-binding compounds
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
NZ520754A (en) 2000-02-10 2004-02-27 Panacos Pharmaceuticals Inc Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
GB0022969D0 (en) * 2000-09-19 2000-11-01 Chiron Spa Influenza a virus subtype H16
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7894999B2 (en) * 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
EP1603590A4 (en) * 2003-03-07 2008-08-27 Merck & Co Inc INFLUENZA VIRUS VACCINE
WO2005016238A2 (en) 2003-05-08 2005-02-24 Duke University Severe acute respiratory syndrome
EP1648927A1 (en) 2003-07-21 2006-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Soluble fragments of the sars-cov spike glycoprotein
ES2372633T3 (es) 2003-11-04 2012-01-25 The Administrators Of The Tulane Educational Fund Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i.
US7871626B2 (en) * 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
DE102005060920A1 (de) * 2005-12-18 2007-06-21 Charité - Universitätsmedizin Berlin Peptide für die Wechselwirkung mit alpha-helikalen Coiled-Coil-Strukturen und/oder Coiled-Coil-Sequenzen, davon abgeleitete Mittel und ihre Verwendung
CA2658559A1 (en) * 2006-07-21 2008-04-03 Pharmexa Inc. Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
ZA200909130B (en) 2010-09-29
IL238404A0 (en) 2015-06-30
DK2170365T3 (en) 2016-09-05
KR20160113331A (ko) 2016-09-28
IL202450A0 (en) 2011-08-01
KR101719135B1 (ko) 2017-03-23
EA017957B1 (ru) 2013-04-30
CN101848719A (zh) 2010-09-29
MX2009013635A (es) 2010-05-19
HK1215037A1 (zh) 2016-08-12
US8604165B2 (en) 2013-12-10
US20140194347A1 (en) 2014-07-10
KR101660363B1 (ko) 2016-09-28
PT2170365T (pt) 2016-07-12
US9353157B2 (en) 2016-05-31
HUE029921T2 (en) 2017-04-28
EP2170365A1 (en) 2010-04-07
JP5764621B2 (ja) 2015-08-19
IL202450A (en) 2015-05-31
KR20150117303A (ko) 2015-10-19
ES2581381T3 (es) 2016-09-05
WO2009002516A1 (en) 2008-12-31
EA201070053A1 (ru) 2010-08-30
EP2170365B1 (en) 2016-05-25
EP2170365A4 (en) 2012-05-02
US20100152109A1 (en) 2010-06-17
CN105237629B (zh) 2019-06-18
CA2691358A1 (en) 2008-12-31
KR20180021930A (ko) 2018-03-05
CN105237629A (zh) 2016-01-13
CN101848719B (zh) 2015-09-23
JP5450402B2 (ja) 2014-03-26
JP2010531362A (ja) 2010-09-24
CA2691358C (en) 2017-08-22
KR20100056442A (ko) 2010-05-27
HK1142804A1 (zh) 2010-12-17
JP2013241432A (ja) 2013-12-05
IL238404A (en) 2017-03-30
AU2008269081A1 (en) 2008-12-31
BRPI0813922A2 (pt) 2017-05-09
PL2170365T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
MX363240B (es) Composiciones que inhiben la influenza y métodos.
WO2002008251A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
WO2007048857A8 (es) USO DE PÉPTIDOS INHIBIDORES DE TGF- βl EN LA PREPARACIÓN DE UN AGENTE MODULADOR DE LA RESPUESTA INMUNE
MXPA03000626A (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
WO2009025117A1 (ja) Cdca1ペプチド及びこれを含む薬剤
WO2009046220A3 (en) Lipopeptides for delivery of nucleic acids
MXPA04000597A (es) Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
WO2010034105A8 (en) Hepatitis c inhibitor compounds
WO2009025116A1 (ja) Cdh3ペプチド及びこれを含む薬剤
WO2005074626A3 (en) Compositions, methods and uses for a novel family of peptides
MX337756B (es) Peptido de epitope hig2 y urlc10 y vacunas que contienen el mismo.
IL173969A0 (en) Use of peptides derived from the a alpha or b beta chain of human of human fibrinogen for the treatment of shock
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
WO2005002500A3 (en) Inhibitors of coronavirus
RU2005123050A (ru) Супер-антигенные фьюжн-белки и их использование
WO2006090090A3 (fr) Epitopes de vih et composition pharmaceutique les contenant
WO2004087054A3 (en) Methods for modulating gastric secretion using prokineticin receptor antagonists.
MX2022002842A (es) Composiciones y metodos para el tratamiento del virus sincitial respiratorio.
FR2828405B1 (fr) Vaccin anti-coronavirus